Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways | Zendy

Liang Yang | Zendy; Yue Hu | Zendy; Guanbao Zhou | Zendy; Qi Chen | Zendy; Zhenshun Song | Zendy

Open Access

Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways

Author(s) -

Liang Yang,

Yue Hu,

Guanbao Zhou,

Qi Chen,

Zhenshun Song

Publication year - 2020

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20193137

Subject(s) - mapk/erk pathway , protein kinase b , pi3k/akt/mtor pathway , biology , p38 mitogen activated protein kinases , signal transduction , cell cycle , apoptosis , cell growth , kinase , cancer research , mtt assay , protein kinase a , microbiology and biotechnology , biochemistry

Hepatocellular carcinoma (HCC) is the dominant pathological type of primary liver cancer and no effective methods are available for its treatment. Erianin is a natural product extracted from Dendrobium, which possesses multiple pharmacological activities, including antioxidative and antitumor activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research